Full Breakdown
Medtronic Reports Record Top-Line Growth in FY26 and Projects Moderate FY27 Expansion
6/4/2026, 9:44:47 PM
FY26 Q4 Earnings Beat
Medtronic posted fiscal Q4 2026 revenue of $9.8 billion, a 10 % year-over-year rise, and adjusted earnings per share of $1.55, matching consensus. Net income was $1.24 billion. The results topped the LSEG consensus of $9.63 billion, prompting a 5-6 % post-market share gain.
Core Business Segment Growth
The cardiovascular unit generated $3.8 billion, up 13.8 % YoY, driven by a 78 % surge in cardiac ablation and a 145 % rise in pulsed-field ablation sales. Neuroscience revenue reached $2.75 billion (+5 %), MedSurg $2.39 billion (+8 %), and diabetes sales climbed 15 % to $837 million.
Full-Year Financial Summary & FY27 Outlook
Full-year 2026 revenue was reported between $36.33 billion and $36.4 billion, an 8.4 % increase, with organic growth near 6 %. Adjusted operating margin fell to 25.5 % amid tariff and payment impacts. The board raised the quarterly dividend to $0.72 per share. FY27 guidance projects 6.75-7.25 % organic revenue growth and non-GAAP EPS of $5.90-$6.00, below the $6.06 consensus.
Executive and Board Remarks
CEO Geoff Martha said the results showed the strongest top-line growth in a decade, crediting disciplined execution and investment, and noted the firm aims to “completely surround the electrophysiology space.” CFO Thierry Piéton projected the recent acquisitions will add about $150 million of inorganic revenue in FY27. Earlier in the year, Medtronic closed the $585 million acquisition of CathWorks and a $650 million cash purchase of SPR Therapeutics, expanding its neuromodulation and peripheral-nerve-stimulation capabilities. The board highlighted deliberate strategic choices behind the dividend increase.
Analyst Reactions and Criticisms
BTIG upgraded Medtronic to Buy with a $90 target, citing steady organic growth. Needham kept a bullish stance with a $120 target, while Goldman Sachs issued a neutral rating and an $84 target, noting the stock trades at a discount to peers and that FY27 EPS guidance falls short of consensus. Analysts warned that tariffs and margin pressure could curb profitability.
Conflicting Figures and Data Gaps
Revenue is cited as $36.33 billion (AP), $36.36 billion (MedTech Dive), $36.4 billion (Medical Device Network), and $33.5 billion elsewhere. Q4 revenue appears as $9.8 billion and $9.81 billion. Dividend yield is reported as 8 % in one source versus roughly 3.9 % elsewhere. These discrepancies stem from differing reporting periods and conventions.
Verbatim Quotes
“Through a dynamic macro environment, we have executed, and we've executed with discipline to deliver an excellent fiscal ‘26 that will continue into fiscal ‘27,” — Geoff Martha, CEO
“Our performance reflects the strongest annual top-line growth Medtronic has delivered in 10 years, powered by disciplined execution across our portfolio and continued operational rigor,” — Geoff Martha, CEO
“CFO Thierry Piéton said M&A will add about $150 million to inorganic revenue growth in fiscal year 2027.” — Thierry Piéton, CFO
Strategic Outlook and M&A Activity
Medtronic completed three acquisitions in 2026, notably the $585 million purchase of CathWorks and a $650 million cash deal for SPR Therapeutics, adding peripheral-nerve-stimulation technology. The firm also advanced pipeline projects such as the Hugo robotic-assisted surgery system and intracardiac echocardiography catheters, supporting the FY27 growth target.
